FDA 483 - Cilag AG - September 23, 2024

An FDA inspection of Cilag AG, a drug product manufacturer in Schaffhausen, Switzerland, occurred from approximately September 17-23, 2024. This inspection resulted in an FDA Form 483, highlighting significant observations concerning the firm's adherence to regulatory standards for drug manufacturing.

The main violations identified pertained to inadequate procedures for preventing microbiological contamination of sterile drug products. Specific issues included insufficient sterilization of product contact parts, improper aseptic techniques during manufacturing operations, and unoptimized filling processes. The environmental monitoring system in aseptic areas was also cited as inadequate, with critical locations lacking proper monitoring. Additionally, the examination and testing of samples were found deficient, specifically concerning the qualification of visual inspection procedures for drug product vials, which lacked an appropriate training kit. Finally, the facility's equipment, particularly the MS filling line, was not adequately maintained, showing discoloration and corrosion.

These observations indicate a need for comprehensive corrective actions under the Current Good Manufacturing Practices (CGMP) framework. Cilag AG is required to respond to the FDA with detailed corrective and preventive actions to address these deficiencies and ensure product quality and safety.